Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Operating Leases: 2018-2025

Historic Operating Leases for Summit Therapeutics (SMMT) over the last 8 years, with Sep 2025 value amounting to $2.7 million.

  • Summit Therapeutics' Operating Leases fell 35.63% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 35.63%. This contributed to the annual value of $3.5 million for FY2024, which is 4.95% up from last year.
  • Latest data reveals that Summit Therapeutics reported Operating Leases of $2.7 million as of Q3 2025, which was up 11.21% from $2.4 million recorded in Q2 2025.
  • In the past 5 years, Summit Therapeutics' Operating Leases registered a high of $5.8 million during Q1 2024, and its lowest value of $351,000 during Q1 2021.
  • Moreover, its 3-year median value for Operating Leases was $3.5 million (2024), whereas its average is $3.7 million.
  • Per our database at Business Quant, Summit Therapeutics' Operating Leases soared by 2,154.67% in 2021 and then tumbled by 51.47% in 2025.
  • Over the past 5 years, Summit Therapeutics' Operating Leases (Quarterly) stood at $1.7 million in 2021, then soared by 63.39% to $2.8 million in 2022, then grew by 19.07% to $3.3 million in 2023, then rose by 4.95% to $3.5 million in 2024, then slumped by 35.63% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $2.4 million for Q2 2025, and $2.9 million during Q1 2025.